Quantum Genomics receives financial aid from Bpifrance (France Public Innovation Bank) for its research program evaluating combinations of its new class of molecules with other anti-hypertensive compounds

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it received a 260 K€ subsidized financing from Bpifrance for its research program assessing combinations of BAPAIs (Brain Aminopeptidase A Inhibitors) with other anti-hypertensive compounds.

Télécharger le pdf